GleamWall
中文EN

PULM Pulmatrix, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1574235 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.0%
TTM net income YoY32.3%
TTM EPS YoY32.3%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-125.1%
Net margin-122.5%
FCF margin-142.4%
EBITDA margin-123.7%

Returns

ROE-71.0%
ROA-43.5%
ROIC (approx.)—
Asset turnover0.36x

Leverage & solvency

Liabilities / assets10.0%
Debt / equity0.00x
Current ratio10.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.12x
Accruals ratio5.3%
Payout ratio—
Capex / revenue5.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$7.81M
R&D expense$38,000$7.17M
SG&A expense$5.13M$7.79M
Operating income-$5.17M-$9.76M
Income tax$0—
Net income-$5.16M-$9.56M
EBITDA—-$9.66M
EPS (basic)-1.41-2.62
EPS (diluted)-1.41-2.62
Weighted avg. shares (diluted)3.65M3.65M
Banking
Net interest income—$467,000
Balance sheet
Cash & equivalents$4.09M$9.52M
Current assets$4.13M$9.92M
Total assets$4.14M$9.94M
Current liabilities$329,000$929,000
Total liabilities$329,000$996,000
Shareholders' equity$3.81M$8.95M
Shares outstanding3.65M3.65M
Cash flow statement
Operating cash flow-$5.43M-$10.72M
Capital expenditure—$398,000
Free cash flow—-$11.11M
Investing cash flow—-$398,000
Depreciation & amortization—$106,000
Stock-based compensation$25,000$511,000

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.